Skip to main content

AstraZeneca Joins Canadian Personalized Oncology Consortium

NEW YORK (GenomeWeb) – Canadian molecular diagnostics firm Contextual Genomics and the Personalized Medicine Initiative today announced that AstraZeneca has joined their National Access Project consortium.

AstraZeneca has provided a grant for an undisclosed amount and will provide technical advice as part of its commitment to the project.

The National Access Project for Cancer Testing, managed by the Personalized Medicine Initiative with testing provided by Contextual Genomics, launches this month. The consortium's goal is to make genomic testing available to any Canadian diagnosed with cancer to improve precision in diagnosis, enable tailored treatment options, and support better health outcomes.

The program will provide a free 90-mutation genomic tumor profiling test for 2,000 cancer patients at ten centers across Canada.

Additional companies are expected to join the National Access Project consortium, the organizations said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.